Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome.

ABSTRACT: BACKGROUNDGlucagon-like peptide-2 (GLP-2) analogs are used clinically to enhance nutrient absorption in patients with short bowel syndrome (SBS); however, the precise mechanism remains unclear. To address this, the study aimed to clarify the dynamics of intestinal epithelial cells and immune cells in patients with SBS treated with GLP-2 analogs.METHODSFive male patients diagnosed with SBS, all of whom received treatment with the GLP-2 analog teduglutide, were included in the study. We conducted longitudinal single-cell RNA sequencing (scRNA-Seq) analysis of intestinal tissue from patients with SBS over a year, integrating microbiome composition analysis.RESULTSAfter treatment, the α-diversity of the gut microbiome increased, indicating a more varied microbial environment. ScRNA-Seq analysi

SUBMITTER: Kudo Y 

PROVIDER: S-EPMC12487850 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature